Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Isis Pharmaceuticals Inc

+ Add to Watchlist

ISIS:US

67.0300 USD 0.7300 1.08%

As of 10:14:00 ET on 05/26/2015.

Snapshot for Isis Pharmaceuticals Inc (ISIS)

Open: 67.3900 Day's Range: 66.8400 - 68.3700 Volume: 264,323
Previous Close: 67.7600 52wk Range: 26.5700 - 77.8000 1-Yr Rtn: +141.25%

Stock Chart for ISIS

No chart data available.
  • ISIS:US 67.0300
  • 1D
  • 1M
  • 1Y
67.7600
Interactive ISIS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ISIS

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.0838
Est. EPS (USD) (12/2015) -0.3170
Est. PEG Ratio -
Market Cap (M USD) 8,111.78
Shares Outstanding (M) 119.71
30 Day Average Volume 2,317,430
Price/Book (mrq) 29.0669
Price/Sale (ttm) 31.8730
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/04/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ISIS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ISIS

Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.

Stanley T Crooke "Stan"Chairman/President/CEO/FounderB Lynne ParshallCOO/Secretary
Sarah BoyceChief Business OfficerElizabeth L HougenSenior VP:Finance/CFO
More Company Profile & Key Executives for ISIS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil